Cenobamate (YKP3089) and Drug-Resistant Epilepsy: A Review of the Literature

Cenobamate (CNB), ([(R)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl], is a novel tetrazole alkyl carbamate derivative. In November 2019, the Food and Drug Administration approved Xcopri(®), marketed by SK Life Science Inc., (Paramus, NJ, USA) for adult focal seizures. The European Medicines Agency...

Descripción completa

Detalles Bibliográficos
Autores principales: Rissardo, Jamir Pitton, Fornari Caprara, Ana Letícia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456719/
https://www.ncbi.nlm.nih.gov/pubmed/37629678
http://dx.doi.org/10.3390/medicina59081389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456719/
https://www.ncbi.nlm.nih.gov/pubmed/37629678
http://dx.doi.org/10.3390/medicina59081389

Ejemplares similares